Institutes outside Greece
Epidemiology, treatment options and outcome of invasive infections caused by Aspergillus section Usti
Abstract
dc:descriptionInvasive aspergillosis (IA) is an important cause of mortality, primarily affecting patients with hematological malignancies and transplant recipients. Among the different Aspergillus species, A. fumigatus and A. flavus account for the majority of cases. Aspergilli belonging to section Usti (ustus group) are rare causes of IA that have recently been reported as emerging pathogens, particularly among transplant recipients receiving antifungal prophylaxis, especially posaconazole. In Switzerland, the latter is prescribed prophylactically to prevent the development of aspergillosis in bone marrow transplant recipients. The aim of this thesis was to describe the European epidemiology of IA caused by Aspergillus species of the ustus group, their clinical characteristics, the treatments administered, and patient outcomes. From a microbiological perspective, the objectives were to identify the species responsible for IA, characterize their antifungal susceptibility profiles, and investigate the synergistic activity of antifungal combinations. We identified cases in which an Aspergillus isolate belonging to the ustus group was recovered from a clinical specimen in Switzerland and other European countries (19 hospitals across 8 countries) over a 10-year period (2007–2018). Among the 90 cases identified, 27 met the criteria for probable or proven IA (EORTC/MSG criteria). An additional 45 cases were identified through a systematic literature review. Pooled analysis of these 72 cases of IA showed that most affected patients were bone marrow transplant recipients (47%) or solid organ transplant recipients (33%), while only 8% were neutropenic. Nearly half (47%) were receiving antifungal prophylaxis, predominantly posaconazole. The lung was the main organ involved; however, secondary dissemination, particularly to the skin and brain, occurred in approximately one-third of cases.Regarding therapeutic management, the main antifungal treatment administered (defined as the first antifungal agent administered for at least 10 days) was amphotericin B in 39% of cases and voriconazole in 36%. Overall mortality at 24 weeks was 58%. Mortality was significantly higher among bone marrow transplant recipients, in patients with proven infection, and among those receiving amphotericin B. However, patients treated with amphotericin B were more severely immunosuppressed (with a higher proportion of bone marrow transplant recipients) and had more severe infections (with higher proportions of proven and disseminated infections in this group), which may explain the excess mortality observed in this category. In parallel, whenever the clinical isolate was available, it was sent to the Institute of Microbiology at CHUV in Lausanne. Species-level identification of the isolates (by sequencing the β-tubulin and calmodulin genes) showed that A. calidoustus was by far the predominant species of the ustus group causing IA, followed by isolated cases of A. pseudodeflectus and A. ustus sensu stricto. Regarding antifungal susceptibility, assessed using the CLSI method, amphotericin B was the most active antifungal agent in vitro. Azoles exhibited lower activity, although isavuconazole showed the highest activity among the azoles, followed by voriconazole and posaconazole. For a subset of Aspergillus calidoustus isolates, in vitro synergistic activity between voriconazole and terbinafine was demonstrated using the checkerboard microdilution method and subsequently validated in vivo in a Galleria mellonella larval infection model. In conclusion, IA caused by Aspergillus species of the ustus group occurs predominantly in the post-transplant setting, generally in the absence of agranulocytosis and frequently in patients receiving posaconazole prophylaxis. Extrapulmonary dissemination is common. The predominant pathogen within this group is A. calidoustus. Among the available therapeutic options, amphotericin B demonstrates the greatest in vitro activity. However, the findings of this thesis suggest that azoles—particularly isavuconazole or voriconazole, either alone or in combination with terbinafine—remain therapeutic alternatives that should be considered in selected cases, such as probable IA, non-disseminated infection, and infection in less severely immunosuppressed hosts.
Degree
thesis:*- Grantor dc:publisher
- Institutes outside Greece
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Glampedakis, Emmanouil
- Γλαμπεδάκης, Εμμανουήλ
Subjects
dc:subject × 27- ΑΣΠΕΡΓΙΛΛΩΣΕΙΣ
- Ανοσοκαταστολή
- Μεταμοσχεύσεις αιματοποιητικών κυττάρων
- Μεταμοσχεύσεις συμπαγών οργάνων
- Αντοχή στις αζόλες
- Αζόλες
- Ασπέργιλλος
- Τερμπιναφίνη
- Azole-resistant aspergillosis
- Invasive aspergillosis
- Immunosuppression
- Hematopoietic cell transplantation
- Solid organ transplantation
- Azoles
- Aspergillus
- Azole resistance
- Terbinafine
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Γενική και Εσωτερική ιατρική
- Επιστήμες Υγείας
- Λοιμώδη νοσήματα
- Clinical Medicine
- Medical and Health Sciences
- General and Internal Medicine
- Health Sciences
- Infectious Diseases
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62568